TWI863110B - 用於製備選擇性雌激素受體降解劑之方法 - Google Patents

用於製備選擇性雌激素受體降解劑之方法 Download PDF

Info

Publication number
TWI863110B
TWI863110B TW112103450A TW112103450A TWI863110B TW I863110 B TWI863110 B TW I863110B TW 112103450 A TW112103450 A TW 112103450A TW 112103450 A TW112103450 A TW 112103450A TW I863110 B TWI863110 B TW I863110B
Authority
TW
Taiwan
Prior art keywords
compound
salt
formula
trifluoromethyl
phenyl
Prior art date
Application number
TW112103450A
Other languages
English (en)
Chinese (zh)
Other versions
TW202346300A (zh
Inventor
德爾加多 阿隆索 喬瑟 阿蓋爾
道格拉斯 派頓 可吉爾
尼可拉斯 安德魯 馬格努斯
寶麗斯 阿諾多維奇 茲凱斯
麥 坎 古元 霍克
陸愈
大衛 麥可 雷米克
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202346300A publication Critical patent/TW202346300A/zh
Application granted granted Critical
Publication of TWI863110B publication Critical patent/TWI863110B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
TW112103450A 2022-02-01 2023-02-01 用於製備選擇性雌激素受體降解劑之方法 TWI863110B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22

Publications (2)

Publication Number Publication Date
TW202346300A TW202346300A (zh) 2023-12-01
TWI863110B true TWI863110B (zh) 2024-11-21

Family

ID=85382684

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112103450A TWI863110B (zh) 2022-02-01 2023-02-01 用於製備選擇性雌激素受體降解劑之方法
TW113140271A TW202523669A (zh) 2022-02-01 2023-02-01 用於製備選擇性雌激素受體降解劑之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113140271A TW202523669A (zh) 2022-02-01 2023-02-01 用於製備選擇性雌激素受體降解劑之方法

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TWI863110B (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654866B2 (en) * 2018-07-12 2020-05-19 Eli Lilly And Company Selective estrogen receptor degraders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709021B1 (en) 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
CN103582637B (zh) * 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
MD3820874T2 (ro) 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
CN115175679A (zh) 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
CN115867282B (zh) * 2020-03-26 2025-05-27 奈克斯拉制药英国有限公司 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10654866B2 (en) * 2018-07-12 2020-05-19 Eli Lilly And Company Selective estrogen receptor degraders

Also Published As

Publication number Publication date
JP7387926B2 (ja) 2023-11-28
MX2024009453A (es) 2024-08-09
CA3243621A1 (en) 2023-08-10
EP4472982A1 (en) 2024-12-11
US11926634B2 (en) 2024-03-12
JP2023112696A (ja) 2023-08-14
KR102743629B1 (ko) 2024-12-17
AU2025234145A1 (en) 2025-10-02
KR20250006312A (ko) 2025-01-10
US20230242545A1 (en) 2023-08-03
DOP2024000150A (es) 2024-08-30
AU2023216654B2 (en) 2025-09-25
JOP20240169A1 (ar) 2024-07-30
TW202523669A (zh) 2025-06-16
KR20240135862A (ko) 2024-09-12
CO2024009411A2 (es) 2024-07-29
JP2023162334A (ja) 2023-11-08
IL313886A (en) 2024-08-01
CR20240283A (es) 2024-09-03
WO2023150056A1 (en) 2023-08-10
JP7805336B2 (ja) 2026-01-23
TW202346300A (zh) 2023-12-01
PE20241731A1 (es) 2024-08-19
AU2023216654A1 (en) 2024-07-11
JP2025183283A (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
TWI863110B (zh) 用於製備選擇性雌激素受體降解劑之方法
CN110041333B (zh) 溴结构域抑制剂化合物及其用途
CN102482221B (zh) 作为katii抑制剂的双环和三环化合物
JP2022513934A (ja) 置換複素環縮合γ－カルボリンの合成
EP3898581B1 (en) Substituted heterocycle fused gamma-carbolines synthesis
JP7347852B2 (ja) 重水素化大環状化合物の調製方法
EP3377480A1 (en) 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
CN107176955A (zh) 一种巴瑞替尼的制备方法
JP6332818B2 (ja) チカグレロルの中間体およびその製造法、およびチカグレロルの製造法
CN107548393B (zh) 适用于治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物
KR101357392B1 (ko) 합성 중간체로서의 티아졸릴-피라졸로피리미딘 화합물 및 관련 합성 방법
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
CN117677616A (zh) 制备血红蛋白调节剂的方法
CN1914213B (zh) 噻唑并嘧啶的制备方法
BR112024013443B1 (pt) Processos para a preparação de degradadores seletivos de receptores de estrogênio
CN102216274A (zh) (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
BR122025017409A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
BR122025017416A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
CN118647619A (zh) 选择性雌激素受体降解剂的制备方法
JP6375374B2 (ja) ピリミジン中間体の製造方法
AU2013363731B2 (en) An improved process for making zilpaterol
TW202527939A (zh) 單一的軸向不對稱化合物之選擇性製造方法
JP2003221394A (ja) キヌクリジン誘導体の製造方法
KR20170044166A (ko) 3-페닐/헤테로아릴-6-페녹시-8-알킬아미노-이미다조[1,2-ｂ]피리다진 유도체의 제조 방법